Comparison
DSIP vs. TB-500
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Healing
CAS no.
62568-57-4
no data
Molecular weight
848.81 g/mol
888 g/mol
Half-life
0.1 h
no data
Sequence
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-GluAc-LKKTETQMechanism of action
DSIP
DSIP was described in 1977 by the Schoenenberger-Monnier group in Basel as a blood-borne substance reported to induce EEG changes similar to delta sleep in animal models. The exact mechanism remains undefined to this day: no defined receptor, proposed modulation of opioid, GABAergic and glutamatergic systems. Most mechanistic findings stem from preclinical studies of the 1980s and 1990s and were later subjected to contested replication attempts.
TB-500
Synthetic fragment of the endogenous protein Thymosin Beta-4. In preclinical models, an influence on cell migration, actin sequestration and neovascularisation has been described. Robust human pharmacokinetic data are not publicly available.
Evidence base
Highest evidence
Human trial
Animal model
Studies
4
3
of which in humans
1
0
Effects recorded
3
4
Open conflicts
1
1
Documented adverse events
1
2